$SOPH

SOPHiA GENETICS and Myriad Genetics collaborate to develop a prostate cancer companion diagnostic using PrGIS, a biomarker for homologous recombination deficiency. Myriad's MyChoice CDx test, currently used in ovarian cancer, will be expanded for prostate cancer. The partnership aims to evaluate PrGIS in clinical trials and enable global laboratory testing. Myriad will present research at the European Society for Medical Oncology Congress 2026.

HC Wainwright & Co. reiterated a Buy rating and $14 price target for Sophia Genetics, implying 88.9% upside from the Oct 9 close. The firm cited strong U.S. revenue growth potential and innovative oncology applications as key drivers.

Myriad Genetics (NASDAQ:MYGN) and SOPHiA GENETICS (NASDAQ:SOPH) are collaborating with AstraZeneca (NYSE:AZN) to advance prostate cancer biomarker PrGIS. Myriad's MyChoice CDx test will produce the PrGIS score, and SOPHiA will integrate it into its cloud-based platform. The companies plan to present research at ESMO 2026.

SOPHiA GENETICS SA (SOPH) reported Q2 2026 revenue of $23.3 million, up 27%, and an adjusted EBITDA loss of $8.8 million. Platform analysis volume rose 22% to 115,000 patient analyses. Management raised full-year revenue guidance to $94 million to $96 million and reaffirmed adjusted EBITDA loss of $29 million to $32 million, citing U.S. in-house testing demand and biopharma growth.

Biotech stocks hit 52-week highs Aug 4, 2026 after Q2 results or regulatory updates. UFP Technologies (UFPT) rose over 25% to $338.70, reporting Q2 net income $20.9M and sales $174M. InfuSystem (INFU) gained 33% to $12.49 on $36.9M Q2 revenue and 2026 guidance. Replimune (REPL) jumped to $13.86 after a favorable BLA opinion. SOPHiA (SOPH) rose to $6.98 with $23.3M Q2 revenue and 2026 outlook. Parabilis (PBLS) reached $36.69.

SOPHiA GENETICS (Nasdaq: SOPH) reported Q2 2026 revenue of $23.3 million, up 27% year over year, with gross margin of 64.6% reported and 72.1% adjusted. Net loss was $22.4 million and adjusted EBITDA loss was $8.8 million, improving 27%. The company raised 2026 revenue guidance to $94-$96 million and signed AstraZeneca companion diagnostic programs.

SOPHiA GENETICS SA (SOPH) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 SOPHiA GENETICS Reports Second Quarter 2026 Results BOSTON, United States and ROLLE, Switzerland, August 4, 2026 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the second quarter ended June 30,

SOPHiA GENETICS (NASDAQ: SOPH) said it entered a multi-year collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics for precision oncology therapies. SOPHiA will advance its Solid Tumor decentralized CDx and develop a Hematological Oncology application for blood cancer. The programs aim to support commercialization of AstraZeneca therapies.

Biotech stocks hit 52-week highs on July 20, 2026, attributed to upcoming clinical catalysts. Xencor (XNCR) reached $20.26, up 7%, with Phase 2b XENITH-UC interim results expected by year-end 2026. Hemab (COAG) hit $52.15 after positive Phase 2 Sutacimig data. Monopar (MNPR) hit $115 on Phase 3 ALXN1840 Wilson disease results. SOPHiA (SOPH) rose above $6.50; Q1 revenue was $21.7M and 2026 guidance is $92M to $94M.

Camblong Jurgi (Executive Chairman) sold 83,679 shares of SOPHiA GENETICS SA (SOPH) at an average of $6.06 ($5.87–$6.30, $0.51M total) across 5 trades over 2026-06-29 to 2026-06-30 under a Rule 10b5-1 trading plan.